Literature DB >> 12401860

Net renal extraction of asymmetrical (ADMA) and symmetrical (SDMA) dimethylarginine in fasting humans.

Robert J Nijveldt1, Paul A M Van Leeuwen, Coen Van Guldener, Coen D A Stehouwer, Jan A Rauwerda, Tom Teerlink.   

Abstract

BACKGROUND: Recently, the potential importance of dimethylarginines as endogenously produced inhibitors of nitric oxide synthase has become clearer. Interestingly, elevated levels have been reported in patients with vascular disease, but especially in patients suffering end-stage renal disease. Although the kidney obviously seems to play a key role in the elimination of dimethylarginines, clear insight into the renal handling of these compounds is lacking. Thus, our aim was to investigate the renal extraction of dimethylarginines.
METHODS: Plasma concentrations of dimethylarginines were determined in both arterial and renal venous blood in 20 fasting patients with normal renal function. Renal extraction was calculated as the arteriovenous concentration difference divided by the arterial concentration times 100%.
RESULTS: A significant renal extraction was found for both dimethylarginines. Renal extraction was significantly higher for asymmetrical dimethylarginine (ADMA) when compared with symmetrical dimethylarginine (SDMA) (16.2 vs 10.5% respectively, P=0.001). In addition, arterial SDMA concentration, but not ADMA concentration, significantly correlated with arterial creatinine concentration.
CONCLUSIONS: In healthy humans, the kidney contributes to the regulation of plasma levels of dimethylarginines, since both ADMA and SDMA were significantly extracted from the arterial supply. Interestingly, a higher renal extraction of ADMA was found when compared to SDMA extraction, which strongly suggests the presence of an additional catabolic pathway for ADMA in the kidney.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12401860     DOI: 10.1093/ndt/17.11.1999

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  21 in total

Review 1.  Sexual dimorphism in the aging kidney: differences in the nitric oxide system.

Authors:  Chris Baylis
Journal:  Nat Rev Nephrol       Date:  2009-06-02       Impact factor: 28.314

Review 2.  Arginine, arginine analogs and nitric oxide production in chronic kidney disease.

Authors:  Chris Baylis
Journal:  Nat Clin Pract Nephrol       Date:  2006-04

Review 3.  Asymmetric dimethylarginine and reactive oxygen species: unwelcome twin visitors to the cardiovascular and kidney disease tables.

Authors:  Christopher S Wilcox
Journal:  Hypertension       Date:  2012-01-03       Impact factor: 10.190

Review 4.  The role of asymmetric and symmetric dimethylarginines in renal disease.

Authors:  Edzard Schwedhelm; Rainer H Böger
Journal:  Nat Rev Nephrol       Date:  2011-03-29       Impact factor: 28.314

5.  Metabolites Associated With Risk of Developing Mobility Disability in the Health, Aging and Body Composition Study.

Authors:  Rachel A Murphy; Steven Moore; Mary Playdon; Stephen Kritchevsky; Anne B Newman; Suzanne Satterfield; Hilsa Ayonayon; Clary Clish; Robert Gerszten; Tamara B Harris
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2019-01-01       Impact factor: 6.053

6.  Impaired endothelial function and microvascular asymmetrical dimethylarginine in angiotensin II-infused rats: effects of tempol.

Authors:  Dan Wang; Zaiming Luo; Xiaoyan Wang; Pedro A Jose; John R Falck; William J Welch; Shakil Aslam; Tom Teerlink; Christopher S Wilcox
Journal:  Hypertension       Date:  2010-09-13       Impact factor: 10.190

7.  Contribution of symmetric dimethylarginine to GFR decline in pediatric chronic kidney disease.

Authors:  Ellen R Brooks; Shannon Haymond; Alfred Rademaker; Christopher Pierce; Irene Helenowski; Rod Passman; Faye Vicente; Bradley A Warady; Susan L Furth; Craig B Langman
Journal:  Pediatr Nephrol       Date:  2017-12-07       Impact factor: 3.714

8.  Unchanged asymmetric dimethylarginine levels in non-diabetic, premenopausal obese women who have common risk factors for cardiovascular disease.

Authors:  P Cetinalp-Demircan; A Can; Selda Bekpinar; Y Unlucerci; Y Orhan
Journal:  Endocrine       Date:  2007-04       Impact factor: 3.633

Review 9.  Emerging risk factors and markers of chronic kidney disease progression.

Authors:  Florian Kronenberg
Journal:  Nat Rev Nephrol       Date:  2009-12       Impact factor: 28.314

10.  Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease.

Authors:  Jill Melendez Young; Norma Terrin; Xuelei Wang; Tom Greene; Gerald J Beck; John W Kusek; Allan J Collins; Mark J Sarnak; Vandana Menon
Journal:  Clin J Am Soc Nephrol       Date:  2009-04-23       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.